What is UBS's rating on AZN?

UBS rates AZN Buy, a bullish rating, as of Feb 13, 2025.

When did UBS last change its view on AZN?

On Feb 13, 2025, UBS upgrades to Buy from Neutral.

UBS AZN price target and rating history

UBS rates AstraZeneca PLC (AZN) Buy, as of its latest action on Feb 13, 2025. It has published 5 rating actions on AZN since June 2022, including 3 upgrades and 1 downgrade.

Current rating: Buy
Price target: Not stated
Median target, all firms: Too few
Actions on AZN: 5

Every UBS rating on AZN

Feb 13, 2025
UpgradeUBS upgrades to Buy from Neutral
Nov 20, 2024
UpgradeUBS upgrades to Neutral from Sell
Jan 16, 2024
ResumeUBS resumes coverage at Sell
Jul 12, 2023
UpgradeUBS upgrades to Buy from Neutral
Jun 14, 2022
DowngradeUBS downgrades to Neutral from Buy

How other firms rate AZN

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Date
Deutsche Bank	Hold	Sep 15, 2026
RBC Capital Markets	Outperform	Sep 9, 2026
HSBC	Hold	Jul 13, 2026
Citigroup	Buy	Jan 27, 2026

Questions about UBS and AZN

What is UBS's rating on AZN?: UBS rates AZN Buy, a bullish rating, as of Feb 13, 2025.
When did UBS last change its view on AZN?: On Feb 13, 2025, UBS upgrades to Buy from Neutral.

More AZN rating histories

All UBS ratings AZN news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.